Titanium Molecular Etching (TiME) offers high-quality precision and considerable diversity in the number of products which can be manufactured this way, including stent technology and bionic parts.
ACE recently completed a substantial expansion programme in order to cater for the new TiME related work.
“I believe we offer some something different at ACE and something that the medical sector wants to buy,” said Chris Ball, engineering director at ACE.
“It’s a big investment, but one we anticipate will pay dividends, with £300,000 of new business due to be signed off as well as the opportunity to make new contacts aware of our titanium etching technology.”
After a successful 2015, in which sales increased by 20% and 12 new jobs were made with the company, the firm are hoping the addition of TiME will continue to benefit the company’s growth.
Managing director Ian Whateley said:“We intend to build still further in 2016 and the medical technology sector will be a key area for us achieving our objective of hitting £5m turnover.”